Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A primer on HIV type 1-specific immune function and REMUNE

R B Moss1, W K Giermakowska, J R Savary

  • 1The Immune Response Corporation, Carlsbad, California 92008, USA.

AIDS Research and Human Retroviruses
|July 22, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation.

Case reports in medicine·2016
Same author

Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2014
Same author

DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation.

Transplant infectious disease : an official journal of the Transplantation Society·2014
Same author

Current treatment options for invasive aspergillosis.

Drugs of today (Barcelona, Spain : 1998)·2013
Same author

DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient.

Transplant infectious disease : an official journal of the Transplantation Society·2013
Same author

NeuroThera® Efficacy and Safety Trial-3 (NEST-3): a double-blind, randomized, sham-controlled, parallel group, multicenter, pivotal study to assess the safety and efficacy of transcranial laser therapy with the NeuroThera® Laser System for the treatment of acute ischemic stroke within 24 h of stroke onset.

International journal of stroke : official journal of the International Stroke Society·2012

This study explores REMUNE, an immune-based therapy for HIV-1, which may restore immune function lost early in infection. Clinical trials are evaluating its potential for chronic HIV management.

Area of Science:

  • Immunology
  • Virology
  • Therapeutics

Background:

  • HIV-1 infection leads to early loss of antigen recognition, impairing immune responses.
  • Nonprogressive HIV disease highlights the potential for strong immune responses.
  • Highly Active Antiviral Drug Therapy (HAART) is standard care, but may not restore immune function if initiated late.

Purpose of the Study:

  • To investigate the effects of REMUNE, an immune-based therapy, on HIV-1-seropositive individuals.
  • To assess REMUNE's potential to reconstitute HIV-1-specific immune function.

Main Methods:

  • Investigated REMUNE's impact on HIV-1-seropositive individuals.
  • Measured immune responses including delayed-type hypersensitivity, lymphocyte proliferation, Th1 cytokine, and beta-chemokine production.

Related Experiment Videos

  • Ongoing Phase II and Phase III clinical trials involving thousands of participants.

    • Main Results:

    • REMUNE demonstrated stimulation of HIV-1-specific immune function.
    • Observed increases in delayed-type hypersensitivity, lymphocyte proliferation, Th1 cytokine, and beta-chemokine production.

    Conclusions:

    • REMUNE shows promise in stimulating HIV-1-specific immune function.
    • Further clinical testing is crucial to determine REMUNE's utility in chronic HIV-1 management.
    • Immune-based therapies like REMUNE may offer additional treatment options for HIV-1.